Castle biosciences inc.

Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer, and as a member of our board of ...Nov 14, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.Target Audience and Goal Statement. This activity is intended for dermatologists, surgeons, and other members of the multidisciplinary team. The goal of this activity is that learners will be better able to understand current and emerging treatment strategies being evaluated across the spectrum of melanoma and how these strategies …

Oct 19, 2021 · October 19, 2021 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management ...

Castle Biosciences is a high growth, commercial stage molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and ...

12 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma. Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma ...Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average price is $16.38 and its 200-day moving …Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.Castle Biosciences Customer Service Email: [email protected] Call: (412) 820-3050 Billing and Insurance Questions Email: [email protected] Call: 866-788-9007, option #3 For additional information about Castle Biosciences or TissueCypher testing, please go to: …

Research and Development, Castle Biosciences, Inc, Friends-wood, Texas.f Funding sources: This work was funded by Castle Biosciences, Inc, United States. IRB approval status: Each cohort used in the analysis was under a protocol approved by an IRB. Accepted for publication June 26, 2022. Reprint requests: Matthew S. Goldberg, MD, …

Order a test. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 15, 2008 (the “Effective Date”) by and between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and Kristen Oelschlager (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment across multiple therapeutic areas.Castle Biosciences, Inc. (the ‘‘Company,’’ “we,” “us” or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve ...Castle Creek is a portfolio company of Paragon Biosciences, which founded Castle Creek with the vision to deliver transformative therapies to patients with rare genetic dermatologic diseases ...DecisionDx-Melanoma (Castle Biosciences Inc [which also provided funding]) Observational, retrospective cohort of archival specimens; multicenter (n = 16), hospital and community based; patients with resected stage I-III melanoma with minimum of 5 y of follow-up if no recurrence: Nonprobability, convenience (2000-2014)Castle Biosciences, Inc. 505 South Friendswood Drive Suite 401 Friendswood, TX 77546 United States 866 788 9007 https://castlebiosciences.com. Sector(s): ...

Castle Biosciences, Inc. 9,614 followers. 1w. JUST RELEASED: Castle Biosciences announces financial results for the 2nd quarter and six months ended 6/30/2023. Highlights: Q2 2023 revenue ...Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The firm earned $23.48 million during the quarter, compared to the consensus estimate of $23.66 million.Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.Target Audience and Goal Statement. This activity is intended for dermatologists, surgeons, and other members of the multidisciplinary team. The goal of this activity is that learners will be better able to understand current and emerging treatment strategies being evaluated across the spectrum of melanoma and how these strategies …CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. Complete Castle Biosciences Inc. stock information by Barron's. View real-time CSTL stock price and news, along with industry-best analysis.

View a summary page of this 2022 CONTRACT to CASTLE BIOSCIENCES, INC. from the Department of Veterans Affairs.Principal Scientist at Castle Creek Biosciences | Expert in Cell and Gene Therapy Philadelphia, PA. Connect Parin Mehta Process Development Supervisor at Castle Creek Biosciences, Inc. ...

Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...Castle Biosciences Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View CSTL financial statements in full.Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …Nov 2, 2023 · Castle Biosciences Reports Third Quarter 2023 Results. Published: Nov 02, 2023. Q3 2023 revenue increased 66% over Q3 2022 to $61 million. Q3 2023 total test reports increased 52% over Q3 2022. Raising full year 2023 revenue guidance to at least $200 million from at least $180 million. Conference call and webcast today at 4:30 p.m. ET. Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ...29 Jun 2023 ... 1Castle Biosciences, Inc, Friendswood, TX 2Surveillance Research Program, Division of Cancer Control & Population Sciences, National Cancer ...

MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma ...

Castle Biosciences, Inc. 2022 Inducement Plan (Full title of the plan) Derek J. Maetzold . President and Chief Executive Officer . Castle Biosciences, Inc. 505 S. Friendswood Drive, Suite 401 . Friendswood, Texas 77546 (866) 788-9907Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information ...Research and Development, Castle Biosciences, Inc, Friends-wood, Texas.f Funding sources: This work was funded by Castle Biosciences, Inc, United States. IRB approval status: Each cohort used in the analysis was under a protocol approved by an IRB. Accepted for publication June 26, 2022. Reprint requests: Matthew S. Goldberg, MD, …DecisionDx-Melanoma is performed in Castle Biosciences’ CAP accredited, CLIA certified laboratory using formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient ...FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use …Castle Biosciences, Inc. believes this leads to better treatment plan decisions, optimized health outcomes and reduced healthcare costs when compared to traditional clinical and pathologic features.DecisionDx - Melanoma - Castle Test Info. PHYSICIAN LOGIN | RESEARCHER LOGIN. CONTACT A. REPRESENTATIVE. ORDER A. TEST. TissueCypher®. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences. Manufacturing · Texas, United States · 342 Employees. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Castle Biosciences is headquartered in Friendswood, Texas with operations in Phoenix, Arizona. Read More. View Company Info for Free Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to ...In this line, the company recently divested its wholly-owned subsidiary -- Myriad myPath Melanoma, LLC to Castle Biosciences, Inc -- for a total value of $32.5 million in cash.Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Instagram:https://instagram. gsi technologynasdaq fnkovlo dividendbest books for day trading If you’re planning a trip to Disney World, the Magic Kingdom is a must-see. With its iconic Cinderella Castle, thrilling rides, and classic attractions, it’s no wonder why millions of visitors flock to this beloved park each year. how do you buy stock on etradeuranium energy corp share price C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Who can I contact if I have a question? Please call our customer service staff at 866-788-9007 or email [email protected]. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. total energy services Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.80 per share a year ago.Castle Biosciences, Inc. (the ‘‘Company,’’ “we,” “us” or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve ...JUST RELEASED: Castle Biosciences announces financial results for the 3rd quarter and nine months ended 9/30/23. Highlights: Q3 2023 revenue… Liked by Alissa Hicks